Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | CuttingEdgeInfo Reports | The Toolkit for Diabetes MSL Programs (PH130)

The Toolkit for Diabetes MSL Programs (PH130)

Build a world-class diabetes medical science liaison (MSL) program

Today's MSLs are key strategic drivers for diabetes products' and overall company success. Currently, approximately 246 million people worldwide have diabetes; this number is expected to increase to 380 million by 2025, according to the International Diabetes Foundation. Such staggering figures solidify diabetes' position as a primary therapeutic area. They also indicate the value of medical science liaisons who are building relationships within the diabetes medical community.

Perhaps your company plans to enter a new market or maybe your diabetes MSL team needs an upgrade. In either case, The Toolkit for Diabetes MSL Programs provides clear, easy-to-access guidance on all aspects of diabetes MSL program management. The research focuses on these core areas:

* MSL structure and staffing

* MSL budgets

* MSL responsibilities and activities metrics

* KOL relationships and segmentation criteria

* MSL qualifications and experience levels

* KOL compensation

CEI has integrated its leading research in MSLs and thought leader management with a growing expertise in therapeutic areas to create a highly customized, data-driven report. You won't find this information anywhere else! Use The Toolkit for Diabetes MSL Programs to strengthen your diabetes MSL team's structure and operations.

Companies Included in Report

* Amgen

* Bayer Schering Pharma

* Bristol-Myers Squibb

* Eli Lilly

* Merck & Co.

* Novartis

* Novo Nordisk

* Pfizer

* Sanofi-Aventis

* Takeda

Published 2009

102 Pages

250+ Metrics

70+ Charts and Diagrams

Table of Contents
Price: $7,695.00 / €5,143.34

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions